The Current Ratio as of September 2024 (TTM) for AN2 Therapeutics, Inc. (ANTX) is 10.61

According to AN2 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.61. This represents a change of 11.95% compared to the average of 9.48 of the last 4 quarters.

AN2 Therapeutics, Inc. (ANTX) Historical Current Ratio (quarterly & annually)

How has ANTX Current Ratio performed in the past?

The mean historical Current Ratio of AN2 Therapeutics, Inc. over the last ten years is 15.61. The current 10.61 Current Ratio has changed 6.70% with respect to the historical average. Over the past ten years (40 quarters), ANTX's Current Ratio was at its highest in in the June 2022 quarter at 28.17. The Current Ratio was at its lowest in in the March 2021 quarter at 0.

AN2 Therapeutics, Inc. (ANTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of AN2 Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

AN2 Therapeutics, Inc. (ANTX) Average Current Ratio

How has ANTX Current Ratio performed in the past?

The current Current Ratio of AN2 Therapeutics, Inc. (ANTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

AN2 Therapeutics, Inc. (ANTX) Current Ratio vs. Peers

How is ANTX’s Current Ratio compared to its peers?

AN2 Therapeutics, Inc.’s Current Ratio is greater than Aerovate Therapeutics, Inc. (6.51), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (16.16), less than Rezolute, Inc. (11.82), greater than Anebulo Pharmaceuticals, Inc. (5.32), less than Mineralys Therapeutics, Inc. (11.20), less than Molecular Partners AG (14.58), less than Pharvaris N.V. (18.45), greater than PepGen Inc. (7.45), less than PMV Pharmaceuticals, Inc. (19.22), less than Eliem Therapeutics, Inc. (60.41), less than MediciNova, Inc. (18.24),

Build a custom stock screener for AN2 Therapeutics, Inc. (ANTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AN2 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

AN2 Therapeutics, Inc. (ANTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like AN2 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.